A similar immunosuppression regimen involving a CD25 (IL2) targeting monoclonal antibody, Basiliximab, along with glucocorticoid and tacrolimus maintenance therapy, has been shown to be safe but poorly tolerated in ALS patients, as an independent investigative approach (Fournier et al., 2018), as well as part of a separate clinical trial assessing intraspinal grafts of neural precursor cells in ALS patients (Mazzini et al., 2019). Here, IL2 is linked to amyotrophic lateral sclerosis.